Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Growth in Short Interest

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,800 shares, a growth of 1,300.0% from the October 31st total of 200 shares. Based on an average daily trading volume, of 5,400 shares, the days-to-cover ratio is currently 0.5 days.

Clinuvel Pharmaceuticals Price Performance

Shares of OTCMKTS:CLVLY opened at $8.50 on Friday. The stock has a 50 day moving average price of $9.33 and a 200-day moving average price of $9.67. Clinuvel Pharmaceuticals has a 52-week low of $8.00 and a 52-week high of $12.06.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).